Literature DB >> 34735583

[Sclerosing hyperostotic bone disorders].

Daniela Kildal1, Rainer Braunschweig2, Matthias Schaal3, Martin Mack4.   

Abstract

CLINICAL/METHODICAL ISSUE: Diagnosis of sclerosing and hyperostotic bone disorders (SHS) is challenging. The correct and early identification of SHS can have therapeutic, prognostic and, in case of genetic SHS with regard to the risk of inheritance, advisory consequences. STANDARD RADIOLOGICAL
METHODS: For diagnosis, radiographic examinations and supplementary computed tomography (CT) and magnetic resonance imaging (MRI) are used. These are of indicative nature. Definitive diagnosis is usually made by genetic differentiation. METHODICAL INNOVATIONS: In combination with the age of the affected person and the location of the osseous changes the characteristic image criteria are important. These are summarized in groups in this overview. PRACTICAL RECOMMENDATIONS: Projection radiography in two planes is the imaging modality of choice. CT and MR can detect additional differential diagnostic criteria and should be indicated when needed.
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Hyperostosis; Osteopetrosis; Osteopoikilosis; Sclerosing bone dysplasias; Striatal osteopathy

Mesh:

Year:  2021        PMID: 34735583     DOI: 10.1007/s00117-021-00930-3

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  3 in total

1.  Lenz-Majewski syndrome: How a single mutation leads to complex changes in lipid metabolism.

Authors:  Mira Sohn; Tamas Balla
Journal:  J Rare Dis Res Treat       Date:  2016-12-29

2.  Osteopoikilosis-Incidental Finding in the Emergency Department.

Authors:  Ulrich Lüke; Bodo von Ditfurth; Clemens Dumont
Journal:  Dtsch Arztebl Int       Date:  2019-09-27       Impact factor: 5.594

Review 3.  Osteopetrosis: genetics, treatment and new insights into osteoclast function.

Authors:  Cristina Sobacchi; Ansgar Schulz; Fraser P Coxon; Anna Villa; Miep H Helfrich
Journal:  Nat Rev Endocrinol       Date:  2013-07-23       Impact factor: 43.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.